Skip to main content

Posters

October 28, 2020
Pimavanserin, a selective serotonin inverse agonist/antagonist at the 5-HT2A/C receptors, is being actively studied for multiple indications. The CLARITY clinical trial program is evaluating pimavanserin as adjunctive therapy in major depressive disorder (MDD); a Phase 2 trial in patients with MDD…
October 09, 2020
Objective: The primary objective of this study was to evaluate the convergent validity of the Cognition Kit Digit Symbol Substitution Test (DSST) mobile app among patients with major depressive disorder (MDD), compared to the gold-standard paper Pearson WAIS IV DSST. Secondarily, patient…
October 09, 2020
Background: Calming patients (without sedation) and increasing engagement (without overactivation) are important components of the successful treatment of major depressive disorder (MDD). The aim of this analysis was to investigate patient experiences with adjunctive brexpiprazole in MDD, in the…
October 09, 2020
Major depressive disorder (MDD) is challenging to treat. Antidepressants are prescribed to manage symptoms; the first step toward effective treatment is for patients to fill their new prescription (primary adherence). This study describes antidepressant primary adherence (APA). Patients with MDD…
October 09, 2020
Background: Treatment with adjunctive brexpiprazole in major depressive disorder (MDD) has been shown to improve 'patient engagement', a concept related to one‚Äôs energy, interest, and outlook. The aim of this study was to examine whether specific patient characteristics were predictive of an…
October 09, 2020
Background: The NIMH Research Domain Criteria (RDoC) framework could be used to recategorize symptoms across the established DSM criteria for neuropsychiatric disorder indications. This post-hoc analysis combined data for MDD and schizophrenia to examine depressive symptoms across DSM indications.
October 09, 2020
Up to 90% of patients with major depressive disorder (MDD) experience sleep disturbances. CLARITY was a phase 2 study of adjunctive pimavanserin, a 5-hydroxytryptamine2A antagonist/inverse agonist, in patients with MDD and inadequate antidepressant response. This exploratory analysis describes the…
October 09, 2020
BACKGROUND: To understand heterogeneity among the population with major depressive disorder (MDD) and suicidal ideation (SI) or attempt (SA) (MDD+SI/SA), clusters were identified through a data-driven process, and care pathways were described by cluster.
October 09, 2020
BACKGROUND: Esketamine nasal spray was approved for adults with treatment-resistant depression on 03/05/2019. Real-world data on patients initiated on esketamine is limited. METHODS: Adults with major depressive disorder (MDD) were identified in the MarketScan® Databases from 01/01/2010 to 02/29/…
October 09, 2020
Background: Esketamine nasal spray (ESK) plus comprehensive standard of care (SOC) vs placebo plus SOC was studied in two phase 3 antidepressant clinical trials among a sub-population of adults with major depressive disorder and high unmet need (NCT03039192, NCT03097133). Objective: This analysis…
Back to Top